Date: 2016-03-03
Type of information: Development agreement
Compound: small molecule lead structures
Company: Grünenthal (Germany) Axxam (Italy)
Therapeutic area: CNS diseases - Neurological diseases - Inflammatory diseases
Type agreement: development collaboration
Action mechanism:
Disease: pain, inflammatory diseases
Details: * On March 3, 2016, Grünenthal and Axxam announced that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets. The collaboration aims to support Grünenthal’s objective to identify compounds that could help patients with pain or inflammatory diseases. Axxam will apply its integrated and innovative early drug
discovery platform by combining it with its extensive expertise for innovative biological pathways and targets. This will include assay development, screening activities, Hit finding and follow up activities.
Financial terms:
Latest news:
